Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression
Autore:
Fava, M; Rosenbaum, JF; Hoog, SL; Tepner, RG; Kopp, JB; Nilsson, ME;
Indirizzi:
Massachusetts Gen Hosp, Clin Psychopharmacol Unit, Depress Clin & Res Program, Boston, MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 Program, Boston, MA 02114 USA Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co Indianapolis IN USA 46285 Labs, Indianapolis, IN 46285 USA
Titolo Testata:
JOURNAL OF AFFECTIVE DISORDERS
fascicolo: 2, volume: 59, anno: 2000,
pagine: 119 - 126
SICI:
0165-0327(200008)59:2<119:FVSAPI>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; ANXIETY; ANTIDEPRESSANT; MULTICENTER; PLACEBO; FAMILY; TRIAL;
Keywords:
fluoxetine; sertraline; paroxetine; SSRI; antidepressant; anxious depression;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Fava, M Massachusetts Gen Hosp, Clin Psychopharmacol Unit, Depress Clin & Res Program, WAC 812,15 Parkman St, Boston, MA 02114 USA Massachusetts Gen Hosp WAC 812,15 Parkman St Boston MA USA 02114 A
Citazione:
M. Fava et al., "Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression", J AFFECT D, 59(2), 2000, pp. 119-126

Abstract

Background: Major depression with high levels of anxiety (anxious depression) is a common subtype of depression associated with greater psychosocial impairment and poorer response to antidepressant treatment. It is unclear whether in this population there are differences in efficacy or tolerabilityacross selective serotonin reuptake inhibitors. For this reason, using head-to-head acute treatment comparison, we compared efficacy and tolerabilityof fluoxetine, sertraline, and paroxetine among depressed patients with high levels of anxiety. Methods: Patients (N = 108) with DSM-IV major depression and high levels of anxiety (a HAM-D-Anxiety/Somatization Factor score greater than or equal to 7) were randomized to fluoxetine, sertraline, or paroxetine treatment in a double-blind fashion. Changes in overall depressionand anxiety were assessed. Results: Patients demonstrated similar baseline-to-endpoint improvement in HAM-D-17 and HAM-D-Anxiety/Somatization Factor scores. Patients also demonstrated similar change-over-time improvement in HAM-D-17 and HAM-D-Anxiety/Somatization Factor scores, except at week one where fluoxetine- and sertraline-treated patients had statistically significantly greater improvement than paroxetine-treated patients in the HAM-D-Anxiety/Somatization Factor score. There were no significant differences across treatments in percentages of patients with substantial emergence, any worsening, or improvement at endpoint in individual HAM-D Items 9 (agitation),10 (psychic anxiety), and 11 (somatic anxiety). Overall, all treatments were well tolerated. Conclusion: These data showed no significant differencesin efficacy and tolerability of fluoxetine, sertraline, and paroxetine in patients with high levels of baseline anxiety symptoms during the acute treatment of major depression. Each treatment was similarly effective in improving depression in this subtype df patients with anxious depression. (C) 2000 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 08:55:10